nilvadipine has been researched along with Disease Exacerbation in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Heus, RAA | 1 |
| Olde Rikkert, MGM | 2 |
| Tully, PJ | 1 |
| Lawlor, BA | 1 |
| Claassen, JAHR | 1 |
| Dyer, AH | 1 |
| Murphy, C | 1 |
| Segurado, R | 2 |
| Lawlor, B | 2 |
| Kennelly, SP | 1 |
| Kennelly, S | 1 |
| Howard, R | 1 |
| Pasquier, F | 1 |
| Börjesson-Hanson, A | 1 |
| Tsolaki, M | 1 |
| Lucca, U | 1 |
| Molloy, DW | 1 |
| Coen, R | 1 |
| Riepe, MW | 1 |
| Kálmán, J | 1 |
| Kenny, RA | 1 |
| Cregg, F | 1 |
| O'Dwyer, S | 1 |
| Walsh, C | 1 |
| Adams, J | 1 |
| Banzi, R | 1 |
| Breuilh, L | 1 |
| Daly, L | 1 |
| Hendrix, S | 1 |
| Aisen, P | 1 |
| Gaynor, S | 1 |
| Sheikhi, A | 1 |
| Taekema, DG | 1 |
| Verhey, FR | 1 |
| Nemni, R | 1 |
| Nobili, F | 1 |
| Franceschi, M | 1 |
| Frisoni, G | 1 |
| Zanetti, O | 1 |
| Konsta, A | 1 |
| Anastasios, O | 1 |
| Nenopoulou, S | 1 |
| Tsolaki-Tagaraki, F | 1 |
| Pakaski, M | 1 |
| Dereeper, O | 1 |
| de la Sayette, V | 1 |
| Sénéchal, O | 1 |
| Lavenu, I | 1 |
| Devendeville, A | 1 |
| Calais, G | 1 |
| Crawford, F | 1 |
| Mullan, M | 1 |
| Nakazawa, M | 1 |
| Ohguro, H | 1 |
| Takeuchi, K | 1 |
| Miyagawa, Y | 1 |
| Ito, T | 1 |
| Metoki, T | 1 |
| Hanyu, H | 1 |
| Hirao, K | 1 |
| Shimizu, S | 1 |
| Sato, T | 1 |
| Kiuchi, A | 1 |
| Iwamoto, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for nilvadipine and Disease Exacerbation
| Article | Year |
|---|---|
Blood Pressure Variability and Progression of Clinical Alzheimer Disease.
Topics: Aged; Alzheimer Disease; Antihypertensive Agents; Blood Pressure Determination; Cognition Disorders; | 2019 |
Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Cholinergic Antagonists; Cognitive Dysfunction; Disabili | 2020 |
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Cognitive Dysfunction; Disease | 2018 |
Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial.
Topics: Administration, Oral; Adult; Aged; Calcium Channel Blockers; Disease Progression; Female; Follow-Up | 2011 |
Nilvadipine prevents cognitive decline of patients with mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Cognition Disorders; D | 2007 |